Background: Acetaminophen (APAP, paracetamol) is the most commonly used drug for pain and fever in both the United States and Europe and is considered safe when used at registered dosages. Nevertheless, differences between specific populations lead to remarkable changes in exposure to potentially toxic metabolites. Furthermore, extended knowledge is required on metabolite formation after intoxication, to optimize antidote treatment. Therefore, the authors aimed to develop and validate a quick and easy analytical method for simultaneous quantification of APAP, APAP-glucuronide, APAP-sulfate, APAP-cysteine, APAPglutathione, APAP-mercapturate, and protein-derived APAP-cysteine in human plasma by ultraperformance liquid chromatographyelectrospray ionization-tandem mass spectrometry.
INTRODUCTION
Acetaminophen (APAP, N-Acetyl-p-Aminophenol, or paracetamol) is the most commonly used drug for pain and fever in both the United States and Europe. 1 APAP is generally safe when used at registered dosages, thereby titrated on effect, with a maximum of 4 g/d in 4 doses for adults. In children, dosage depends on age and weight as follows: with age ,1 month-30-60 mg$kg 21 $d 21 in 3 doses; with age .1 month-up to 90 mg$kg 21 $d 21 in 4 doses. 2 However, administration of supratherapeutic doses of APAP is the leading cause for liver failure in the United States, 3 mainly influenced by its drug metabolism. This metabolism has been reported to deviate in (premature) neonates, 4 obese patients, 5 and following supratherapeutic doses. 6 Such variability in exposure to potentially toxic metabolites can be expected in other specific populations as well, eg, anorexic patients, patients from different ethnical backgrounds, extreme elderly, pregnant women and their fetuses, 7 and in patients with drugor genetically driven changes in CYP1A2 activity, eg, omeprazole induction.
APAP is largely metabolized in the liver, predominantly by sulfation and glucuronidation (Fig. 1) . In adults, sulfation encompasses approximately 30% and glucuronidation approximately 55% [8] [9] [10] ; only 2%-5% is excreted unchanged in the urine. 9, 10 Approximately 5%-10% of APAP is metabolized by cytochrome P450 (CYP), primarily by CYP2E1, [11] [12] [13] to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). 9, [14] [15] [16] At therapeutic doses, NAPQI is immediately inactivated by conjugation with glutathione. However, without this detoxification route, NAPQI binds covalently to cellular proteins and forms toxic protein adducts, such as protein-derived APAP-cysteine (APAPcysteine). These protein adducts may cause mitochondrial dysfunction and early oxidant stress. [17] [18] [19] Consequently, hepatotoxicity can be caused by liver cell necrosis. 3 Although it was thought that depletion of 70% of total liver glutathione would be necessary for NAPQI to begin with protein binding, 20 protein-derived APAP-cysteine was detected in serum from human after therapeutic doses. 21 It is likely that either a threshold of protein-derived APAP-cysteine needs to be exceeded for the development of toxicity or that specific binding targets are spared at therapeutic doses. 6 Currently, APAP concentrations have only been considered important to measure for patients who are suspected of intake of a toxic amount and for patients who show a decreased hepatic function. In that case, APAP is mostly analyzed with an immunoassay, not measuring metabolites, despite their key role in APAP hepatotoxicity. Considering APAP-metabolic routes, further investigation for associations between exposure to APAP metabolites and toxicity is warranted, as well as exposure in specific populations. In the case of APAP intoxication, extended knowledge of metabolite formation will assist in optimizing (antidote) treatment. This also applies to intoxication on chronic use of high APAP dosages. Currently, there remains a knowledge gap regarding the optimal treatment with N-acetylcysteine infusion to prevent or treat hepatotoxicity. These new insights suggest therapeutic drug monitoring (TDM) of metabolites in case of toxicity, or as part of standard clinical care in certain populations. Ultimately, monitoring of APAP-metabolite concentrations may prevent or reduce toxicity and optimize therapy.
We developed and validated an analytical method for simultaneous quantification of APAP, APAP-glucuronide, APAP-sulfate, APAP-cysteine, APAP-glutathione, APAPmercapturate, and protein-derived APAP-cysteine in a minimal volume of human plasma by ultraperformance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-MS/MS), preceded by an easy sample preparation. We aimed to optimize the sensitivity of the assay to minimize the required sample volume, which allows measurement of the smallest volume samples from preterm infants.
MATERIALS AND METHODS

Chemicals and Reagents
APAP, APAP-sulfate, APAP-mercapturate, APAPglucuronide, and APAP-cysteine solution were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). APAP-glutathione was obtained from Toronto Research Chemicals (Eching, Germany) and APAP-D4 solution from Sigma-Aldrich Cerilliant (Zwijndrecht, the Netherlands). Methanol absolute LC-MS grade and formic acid 99% ULC/MS grade were purchased from Biosolve BV (Valkenswaard, the Netherlands). Water was purified using a MilliPore Advantage A10 system. External quality control (QC) samples for APAP were purchased from Stitching Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie (KKGT, The Hague, the Netherlands) and Santa Cruz Biotechnology (Heidelberg, Germany).
Stock Solutions, Calibrators, QC Samples, and Internal Standard Stock solutions of APAP, APAP-sulfate, APAPglucuronide, and APAP-cysteine were prepared at a concentration of 500 mg/L using methanol, whereas stock solutions of APAP-mercapturate and APAP-glutathione were prepared at a concentration of 100 mg/L using methanol. For each analyte, 2 separate stock solutions were prepared with the same concentration, for both calibration of standard samples and for QC samples. Stock solutions were stored at 2208C.
The working solution, calibrator 8 (50 mg/L), was prepared by drying 500 mL of APAP, APAP-sulfate, APAPglucuronide, and APAP-cysteine, and 2500 mL of APAPmercapturate and APAP-glutathione in 1 glass tube at 408C under nitrogen flow until all methanol was evaporated. Subsequently, all analytes were reconstituted in 5-mL human plasma and mixed for 30 seconds. Calibrators 1 through 7 (0.05-25 mg/L) and the lower limit of quantification (LLOQ) standard (0.01 mg/L) were prepared by diluting calibrator 8 with human plasma. QC samples were prepared the same way, using the other stock solution. The working solution was diluted with human plasma to get 3 concentrations: QC Low (0.20 mg/L), QC Medium (1.5 mg/L), and QC High (15 mg/L). Then, calibrators and QC samples were transferred in 10-mL portions to 1.5-mL tubes (Eppendorf) and stored at 2808C awaiting analysis.
The internal standard (IS) was APAP-D4. A working solution of the IS was prepared in methanol at a concentration of 100 mcg/L APAP-D4.
Specimens
Human blank plasma was obtained from the blood transfusion laboratory of the Erasmus Medical Center Rotterdam. Because APAP is a regularly used drug, APAP-free blood was collected from volunteers. Blood was centrifuged to separate plasma from the red blood cells. Plasma was pooled and collected in smaller tubes. These tubes were stored at 2208C awaiting analysis.
Sample Preparation
All calibrators, QC samples, blank and patient samples were thawed at least half an hour before preparation. Then, to 10 mL of each standard and sample, 40 mL of IS solution was added for protein precipitation. The samples were mixed for 15 seconds and then centrifuged for 5 minutes at 16,000 · g. Approximately 30 mL of supernatant was taken from each sample and transferred to amber autosampler insert vials (VWR). Next, 140 mL of 0.1% aqueous formic acid was added and the samples were mixed for 15 seconds. The ratio of the aqueous and organic solvent in the sample matched the ratio in the mobile phase at start of the gradient. The blank sample, without IS, was prepared by adding 40 mL of methanol instead of IS solution. For APAP, APAP-D4, and APAP-cysteine, 4 mL of sample was injected into the UPLC-MS/MS apparatus. For all the other analytes, 10 mL was injected because of the lower sensitivity for these analytes.
Protein-Derived APAP-Cysteine
For quantification of protein-derived APAP-cysteine in patient samples, the sample preparation was preceded with 1 extra step after thawing the sample: The protein-bound fraction was removed by filtration of an extra 130-mL plasma through an Amicon Ultra-0.5 Centrifugal Filter Unit with Ultracel-10 membrane (Merck Chemicals, Amsterdam, the Netherlands) and discarded afterward, in order to collect 10-mL plasma with unbound APAP-cysteine. The concentration of protein-derived APAP-cysteine is determined by calculating the difference in APAP-cysteine concentrations before and after filtration. The sample was further prepared as described for all other analytes, continuing with the addition of 40 mL of IS.
Instrumentation
The equipment used was a Dionex Ultimate UPLC system consisting of an Ultimate 3000 RS UPLC pump, an Ultimate 3000 RS autosampler, and an Ultimate 3000 RS Column Compartment. The UPLC was connected to a triple quadrupole Thermo TSQ Vantage MS with HESI probe (Thermo Scientific, Waltham, MA). The software programs Chromeleon (version 6.8; Dionex, Thermo Scientific), Xcalibur (version 2.1; Thermo Scientific), and LCquan (version 2.6; Thermo Scientific) were used to control the system and analyze the data.
UPLC Conditions
Chromatographic separation, based on affinity of the analytes with the nonpolar stationary phase, was achieved with a reversed-phase Acquity UPLC HSS T3 column (1.8 mm, 2.1 · 100 mm; High Strength Silica with a bound trifunctional C18 alkyl phase). Gradient elution was performed with a mobile phase consisting of 1 mL of a 154 mg/L solution of ammonium acetate in formic acid (99%) in 1 L of Milli-Q ultrapure water (eluent A) and 1 mL of the same solution in 1 L of methanol (eluent B). Before the analysis, the system was equilibrated at the starting conditions of 86% eluent A and 14% eluent B until pressure was stable. The multistep gradient was as follows: from 0 to 0.8 minutes, eluent B was increased from 14% to 28%; from 0.8 to 1.0 minutes, eluent B was increased to 95%; from 1.0 to 2.0 minutes, eluent B was kept stable at 95%; from 2.0 to 2.2 minutes, eluent B was decreased to 14%; from 2.2 to 5.3 minutes, eluent B was kept stable at 14%. The run ended at 5.3 minutes at starting conditions. The flow was kept at 0.400 mL/min during the entire runtime. The temperature for the column oven was set at 408C and for the autosampler at 158C. To quantify all analytes, a volume of 4 mL as well as 10 mL is injected, which requires 2 runs per sample and therefore doubles the runtime to 10.6 minutes. For the quantification of protein-derived APAP-cysteine, a third run is required.
MS/MS Conditions
For the detection and quantification of APAP and metabolites, settings of the MS/MS were as follows: MS runtime of 4.5 minutes, experiment type was Selected Reaction Monitoring, ionization at ESI+, spray voltage of 4000 V, vaporizer temperature at 3758C, sheath gas pressure with nitrogen at 50 psi, auxiliary gas pressure with nitrogen at 20 psi, capillary temperature at 2508C, and collision pressure at 1.5 mTorr. All other settings were specific for each analyte and were determined by infusion experiments with academic solutions of each analyte of 1 mg/L. The chosen transitions and settings are shown in Table 1 .
Assay Validation
Validation of the method was performed according to the U.S. Food and Drug Administration (2001) guidelines for bioanalytical methods. 22 The following validation parameters were investigated.
Linearity
The relation between the concentration of the calibrators and response (ratio of peak areas of the analytes and the IS) was tested with a calibration curve. This curve should be linear across the range from 0.05 up to 50 mg/L. To make the calibration curve, 8 calibrators were prepared and analyzed. Linear least square regression was used to analyze the data. It was decided to apply weighting 1/x, which means that calibrators with the lowest concentrations are more important for the calibration line than calibrators with highest concentrations. 23 The relative standard deviation (RSD) was required to be lower than 15%, and the correlation coefficient (r) together with the determination coefficient (r 2 ) were required to be at least 0.9950 and 0.9900, respectively.
LLOQ and ULOQ
The LLOQ was measured by analyzing the LLOQ calibrator (0.01 or 0.05 mg/L) 6 times in a row. Mean and standard deviation of the response ratios of the 6 samples were measured. Imprecision and accuracy were calculated and should be # 20% and between 80% and 120%, respectively. The highest calibrator of the calibration curve was used as upper limit of quantification (ULOQ).
Accuracy
Accuracy was measured by analyzing 3 QC concentrations (n = 6 for each concentration). The percentage deviation between measured concentration and theoretical concentration was calculated and should be lower than 15%.
Repeatability and Reproducibility
Repeatability was tested by analyzing 3 QC concentrations in 6-fold on the same day. For each concentration, mean, and RSD were calculated. Reproducibility was tested by analyzing each QC concentration in duplicate on 6 different days. The mean response of the 12 concentrations for each sample with their RSD was calculated. For both tests, RSD was required to be lower than 15%.
Stability
In-process stability was determined by storing QC samples of 3 concentrations (n = 2 per concentration) at 68C before preparation for 24 and 48 hours. Autosampler stability was determined by storing QC samples (n = 2 per concentration) after sample preparation in the autosampler for 24, 48, and 72 hours. Response ratios were measured and compared with response ratios of samples kept at 2808C before preparation. After sample preparation, samples were directly analyzed. Recovery was required to be between 90% and 110%.
Matrix Effect and Recovery
It is important to measure matrix effects and absolute recoveries in the development of an LC-MS/MS method since ion suppression and ion enhancement effects can be expected owing to interferences by matrix compounds, stable-isotopelabeled internal standards and coeluting compounds. 24 To check whether the precision, the reproducibility, and the stability of the concentration-signal ratio are affected by interference of the matrix analytes, the method described by Matuszewski et al (2003) was used. 25 Five different lots of human plasma were used. To 2 QC concentration levels (QC low and QC high) and a blank sample (all 3 in duplicate), analytes were added before extraction. The same set of QCs and blanks was prepared with the analytes added after extraction. Also, a set of 6 samples was evaluated with only Milli-Q ultrapure water instead of plasma. Matrix effects were calculated as follows: (peak area of analyte spiked after extraction)/ (peak area of analyte prepared in Milli-Q ultrapure water) · 100%.
The recovery was calculated as the percentage ratio of the area of the analytes spiked before extraction and the ones prepared in Milli-Q ultrapure water. The mean and RSD were calculated of both matrix effects and recovery. In the ideal situation, the mean matrix effects and recovery are between 80% and 120% and the RSD of both parameters is # 15%. Furthermore, for each analyte, the IS-normalized matrix effect should also be calculated by dividing the matrix effect of the analyte by the matrix effect of the IS. The RSD of the IS-normalized matrix effect calculated from the different lots of matrix should not be greater than 15%.
Application to Pediatric Pharmacokinetic Samples
For the validation of the assay for clinical practice and research purposes, the method has been applied to quantify APAP and its metabolites in plasma of children participating in a pediatric clinical study. This observational prospective study was performed at the Department of Anaesthesia and Intensive Care Medicine of Our Lady's Children's Hospital, Dublin, Ireland, between January and November 2012. Children (with and without Down's Syndrome) routinely received APAP postcardiac surgery in a dose of 7.7 mg/kg for children below 10 kg bodyweight, and 15 mg/kg for children above 10 kg bodyweight. The study protocol was approved by the local ethics committee.
RESULTS
Linearity
Linearity was achieved for each analyte in the range between the LLOQ and the ULOQ (Table 2) , with all RSDs to be lower than 15% and the determination coefficient (r 2 ) to be 0.998 at the lowest. APAP was linear from calibrator 1 up to and including 7; APAP-mercapturate and APAP-cysteine from calibrator 1 up to and including 6; APAP-sulfate from calibrator 2 up to and including 8; APAP-glucuronide, APAP-glutathione from calibrator 1 up to and including 8. Quantification performance of protein-derived APAP-cysteine is subject to those of APAP-cysteine, with the step of filtration being the single difference.
LLOQ and ULOQ
The results of determination of LLOQ and ULOQ are shown in Table 2 .
Accuracy, Repeatability, and Reproducibility
The accuracy, repeatability, and reproducibility data all met the requirement of being less than 15%, except for the APAP-cysteine accuracy of 30.9% (error of measurement) for QC high. The results are shown in Table 2 . 
Stability
Except for APAP-glutathione, the recovery of all QCs was between 90% and 110%, indicating that they were stable for at least 48 hours when stored at 68C. APAP-glutathione was only stable for 24 hours. All prepared QCs were stable for at least 48 hours when kept in the autosampler. The effect of drying showed no significant difference between the dried and nondried standard (Mann Whitney test; P , 0.05).
Matrix Effect and Recovery
Matrix effects and absolute recoveries in the development of the LC-MS/MS method are shown in Table 3 . The test of Matuszwewski showed that APAP, APAP-cysteine, and APAP-sulfate experienced neither matrix effect nor an effect from the sample preparation. Concerning APAP-glucuronide though, 191.2% matrix effect indicates ion enhancement. However, for APAP-mercapturate, ion suppression was observed; matrix effect was 72.0%. A good recovery was achieved for all analytes, except for APAP-glutathione with mean 18.6%.
Application to Pediatric Pharmacokinetic Samples
A total of 162 postdose samples were collected from a pediatric cohort (n = 30), consisting of children with Down's Syndrome (n = 17) and without Down's Syndrome (n = 13) (data unpublished); median age at surgery was 176 days (range, 92-944), median weight at cardiac surgery 6.1 kg (4-12.9).
For APAP, APAP-cysteine, APAP-glucuronide, and APAP-sulfate, only 1 of the 162 (0.6%) samples was measured below LLOQ. For APAP-mercapturate and APAP-glutathione, this was the case in 5 (3.1%) and 161 (99.4%) samples, respectively. None of the analytes was measured above the ULOQ in these samples. Because of the small sample volume, it was not possible to differentiate between protein-bound and protein-unbound APAP-cysteine.
DISCUSSION
We have validated an UPLC-MS method for the quantification of APAP and its metabolites according to U.S. Food and Drug Administration guidelines, with an easy sample preparation, short runtime, and minimal injection volume. Therefore, the assay is very suitable for TDM. The metabolites incorporated in this method are APAP-glucuronide, APAP-sulfate, APAP-glutathione, APAP-cysteine, APAP-mercapturate, and protein-derived APAP-cysteine. Previous reported methods for the quantification of APAP and metabolites in human plasma contained few metabolites, mostly APAP-sulfate and/or glucuronide. [26] [27] [28] Assays with more metabolites were prior validated in animal matrices, 29 although Cook et al recently published a method in human plasma and urine that comes close to the performance of our assay. 30 Our assay is distinguished by a shorter total runtime per injection of 5.3 minutes versus 20 minutes, easier sample preparation, and the ability to quantify the toxic metabolite protein-derived APAP-cysteine.
Our assay fulfilled the desired criteria for accuracy, repeatability, and reproducibility, except for the 30.9% accuracy of QC high of APAP-cysteine. This QC high concentration of APAP-cysteine was outside the linear range. The overestimation of APAP-cysteine could be caused by transformation from the instable APAP-glutathione. At therapeutic doses, the APAP ULOQ is generally not exceeded, although it may be for toxicology purposes. The ranges for linearity for all other analytes were perfectly suitable for clinical pharmacology and toxicology.
Relevant matrix effects were measured for APAPglucuronide during the experiment, resulting in an increased process efficiency. This is in line with the general problematic behavior of glucuronide-metabolites in LC-MS/MS analyses, because of their susceptibility to interferences from the coeluting matrix analytes. 31 However, for APAPmercapturate, matrix effects lead to observed ion suppression. The coefficients of variation of APAP-mercapturate in the samples spiked before extraction are 5.8% and 4.7% for QC-L and QC-H, respectively. Therefore, the effect of the matrix can be considered acceptable. For all other analytes, no matrix effects were measured, which indicates the absence of interferences by matrix compounds, stable-isotope-labeled internal standards, and coeluting compounds, that may affect ion suppression and ion enhancement. The matrix effect of plasma is relevant, although it does not influence quantification as all analytes and calibrators are prepared in the same plasma-matrix and are subject to influence to the same extent.
Except for APAP-glutathione, the stability of all analytes was good, which means they were stable for at least 48 hours when stored at 68C. APAP-glutathione was only stable for 24 hours at 68C, and therefore the measurement or storage of the plasma sample in a freezer should be aimed for within 24 hours. This instability has also been reported by Cook et al 30 Hydrolysis of APAP-glutathione quickly transforms APAP-glutathione to APAP-cysteine, presumably by gammaglutamyl transferase and dipeptidases. This may lead to an undervaluation of the actual concentration APAP-glutathione at the time of sample collection and may lead to an increased APAP-cysteine concentration. This instability of APAPglutathione, where APAP-cysteine is formed from APAPglutathione, may also be responsible for the increased recovery and process efficiency of APAP-cysteine and the lower recovery and process efficiency of APAP-glutathione. For future research, the addition of peptidase inhibitors during sample collection could prevent or reduce this degradation. The assay was successfully validated for clinical practice and research purposes, quantifying APAP and its metabolites in 162 plasma samples from children. APAPglutathione could only be quantified in one sample, as a result of rapid conversion into APAP-cysteine. This confirms the relevance of the addition of a peptidase inhibitor during sample collection. APAP-mercapturate could not yet be detected in 5 samples, which were all the first to be collected postdose, as APAP-mercapturate is the last metabolite to be formed. For one sample, which was drawn 4 minutes after the dose, all analytes were below LLOQ. Because APAP was not yet detectable at that time, metabolites could not have been formed either. In conclusion, the assay is performing well for samples in clinical practice.
Quantification of APAP-glutathione during therapeutic as well as toxic dosages of APAP may be relevant, as it plays a crucial role in the formation of toxic metabolites, although quantification of in vivo APAP-glutathione levels has only been reported in animals yet. 29 Normally, the reactive metabolite NAPQI is quickly detoxified by conjugation with glutathione and further converted to the cysteine conjugate before it is acetylated to form APAP-mercapturate. However, when the formation of the reactive metabolite exceeds the glutathione-conjugation capacity of the liver, covalent binding of NAPQI to cellular macromolecules may result, which initiates the events ultimately leading to cytotoxicity.
Nevertheless, protein-derived APAP-cysteine can be measured with our assay if 130 mL of plasma sample is available. Generally, this allows the quantification in adults and older infants, but not in neonates. Protein-derived APAPcysteine is mostly present in hepatocytes and is directly related to toxicity and detectable in serum at therapeutic doses. 6 The interpretation for the treatment or toxicity still remains to be investigated.
More research is needed on the toxic effects and characteristics of APAP metabolites in specific populations where different metabolisms may be expected. These may include patients with anorexia, patients from different ethnic backgrounds, elderly patients, pregnant women and their fetuses, 7 obese adults, 5 preterm infants, [32] [33] [34] patients with possible pharmacokinetic interactions on CYP1A2, and patients subjected to repeated administration of APAP leading to induced CYP enzymes. Repeated administration of APAP at a subtoxic dose may result in an induction of hepatic CYP enzymes CYP2E1, CYP3A, and CYP1A. 35 Generally, for toxicology purposes, APAP concentrations have only been considered important to measure for patients who are suspected for intake of a toxic amount, not its metabolites. Extended knowledge is required about metabolite formation after intoxication to optimize treatment by infusion of the antidote, N-acetylcysteine. TDM of metabolites may be indicated in case of toxicity, or as part of standard clinical care in certain populations where metabolites may be used as a marker for suspected liver injury.
CONCLUSIONS
We have developed a method for the simultaneous quantification of APAP, APAP-glucuronide, APAP-sulfate, APAP-cysteine, APAP-glutathione, APAP-mercapturate, and protein-derived APAP-cysteine in human plasma, which greatly facilitates further research into APAP and metabolites, as well as for TDM purposes, even in the smallest plasma volumes obtained from preterm infants.
